H.R. 3269 · 119th Congress · Commerce
ETHIC Act
- IntroducedMay 8, 2025 Done
- CommitteeReferred to Judiciary Current stage
- House floorNot yet Not reached yet
- Senate floorNot yet Not reached yet
- Chambers agreeNot yet Not reached yet
- PresidentNot yet Not reached yet
Full text
No CRS summary yet · 448 wordsH.R. 3269 · Introduced in House · May 8, 2025
This Act may be cited as the Eliminating Thickets to Increase Competition Act or the ETHIC Act .
(a) Limit on number of patents per patent group that may be asserted in action for infringement. Section 271(e) of title 35, United States Code, is amended by adding at the end the following: (7) (A) A person who brings an action for infringement of a patent under this section against a party described in subparagraph (B) may assert in the action not more than one patent per Patent Group. (B) A party described in this subparagraph is— (i) a person who— (I) submits an application for approval of a drug under subsection (b)(2) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355 ), or is a holder of such an approved application; or (II) submits an application for licensure of a biological product under section 351(k) of the Public Health Service Act ( 42 U.S.C. 262(k) ), or is a holder of such a licensure; or (ii) a person making, using, selling, offering for sale, introducing or delivering into interstate commerce, or importing— (I) a drug approved pursuant to an application under subsection (b)(2) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355 ); or (II) a biological product licensed under section 351(k) of the Public Health Service Act ( 42 U.S.C. 262(k) ). (C) A person who brings an action described in subparagraph (A) asserting a patent against a party may not bring any additional actions described in that subparagraph asserting a patent in the same Patent Group against that party. (D) (i) For purposes of this paragraph, the term Patent Group means 2 or more commonly owned patents or applications that— (I) are identified on 1 or more disclaimers under section 253 to another commonly owned patent; or (II) are subject to 1 or more disclaimers under section 253 to another commonly owned patent. (ii) For purposes of clause (i)(I)— (I) each patent or application that identifies the same patent or application on a disclaimer under section 253 is part of the same Patent Group; and (II) each patent or application that is identified on a disclaimer under section 253 is part of the same Patent Group as the patent or application subject to the disclaimer. .
(b) Applicability. The amendment made by subsection (a) shall apply with respect to an application submitted under subsection (b)(2) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355 ) or section 351(k) of the Public Health Service Act ( 42 U.S.C. 262(k) ) on or after the date of enactment of this Act.
Shown here because the text is under 500 words. Open on Congress.gov
Who lobbies on it
12 organizations, more than 98% of House bills · 45 filings · Q2 2025–Q3 2026These 12 organizations’ PACs gave $44.5K to 5 of the 10 members sponsoring or cosponsoring H.R. 3269 in the 2025–26 election cycle.
One square per quarter since introduction, oldest left. Filled = named it that quarter.
-
Pharmaceutical Research and Manufacturers of America
6 of 6 quarters
“…H.R. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) H.R. 4570: Interagency Patent Coordination and Improvement Act of 2025 H.R. 6485: Skinny Labels, Big Savings Act Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues AI patent policy…”
$26.6M lobbying spend in 2026 to date, all issuesQ3 2026 filing
-
Novartis
6 of 6 quarters
“S. 43: Skinny Labels, Big Savings Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 S. 2276/HR. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) Biopharmaceutical innovation policy issues Bayh-Dole march-in…”
$6.2M lobbying spend in 2026 to date, all issuesQ3 2026 filing
-
Association for Accessible Medicines
6 of 6 quarters
“H.R.3160/S.1553: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act. H.R.3152/S.1546: Patent Eligibility Restoration Act of 2025. H.R.3269/S.2276: Eliminating Thickets to Increase Competition (ETHIC) Act. S.2658: Medication Affordability and Patent Integrity Act. S.1041…”
$2.5M lobbying spend in 2026 to date, all issuesQ3 2026 filing
9 more organizations, every filingPROUpgrade
Organizations that named H.R. 3269 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.
Actions
2 actions · newest first- May 8, 2025Referred to the House Committee on the Judiciary.
- May 8, 2025Introduced in House